hepat
c
viru
hcv
member
flavivirida
famili
envelop
positivestrand
rna
viru
preferenti
replic
hepatocyt
least
million
peopl
worldwid
persist
infect
hepat
c
viru
chronic
hcv
infect
associ
signific
risk
progress
cirrhosi
hepatocellular
carcinoma
antivir
therapi
pegyl
alphainterferon
ribavirin
current
best
therapeut
regimen
success
treat
patient
better
knowledg
viral
host
factor
determin
hcv
clearanc
persist
acut
stage
infect
need
order
improv
antivir
therapi
develop
effici
vaccin
studi
focus
innat
cellular
immun
respons
shown
suffici
larg
hcv
inoculum
abl
evad
subvert
circumv
host
defenc
present
chimpanze
reliabl
experiment
anim
model
initi
posthcv
infect
event
efficaci
vaccin
candid
evalu
shown
hcvspecif
tcell
immun
import
control
hcv
infect
sever
studi
indic
role
humor
immun
acut
stage
hcv
infect
aspect
remain
poorli
character
glycoprotein
thought
viral
attach
protein
thu
main
target
hcvneutral
antibodi
identif
protect
epitop
conserv
across
differ
strain
hcv
therefor
major
challeng
vaccin
design
number
antibodi
capabl
block
bind
cell
cell
receptor
describ
neutral
hcv
entri
anim
cellular
model
cell
entri
shown
involv
sever
surfac
molecul
notabl
includ
tetraspanin
srbi
receptor
although
studi
need
better
understand
viral
entri
occur
might
neutral
detect
neutral
antibodi
human
blood
problemat
effici
reliabl
cell
cultur
system
hcv
becam
avail
henc
develop
vitro
neutral
assay
hcv
could
extrem
valuabl
character
humor
immun
respons
hcv
evalu
potenti
passiv
activ
immun
hepat
c
recent
studi
use
vitro
neutral
assay
system
base
infecti
retrovir
pseudoparticl
hcvpp
bear
hcv
envelop
glycoprotein
confirm
hcvinfect
patient
sera
inde
neutral
infect
howev
also
shown
neutral
activ
antibodi
hcvinfect
patient
attenu
factor
present
human
serum
identifi
highdens
lipoprotein
hdl
fraction
hdl
facilit
hcvpp
entri
postbind
event
suggest
hdl
favour
intern
virion
thu
latter
escap
neutral
antibodi
recent
hcv
cell
cultur
model
hcvcc
develop
allow
product
viru
particl
effici
propag
cell
cultur
preliminari
neutral
assay
carri
author
studi
describ
set
standard
focu
reduct
neutral
assay
base
hcvcc
focu
reduct
assay
wide
use
evalu
neutral
antibodi
respons
virus
form
foci
infect
cell
follow
recent
develop
hcvcc
model
principl
focu
reduct
assay
appli
hcvneutral
antibodi
detect
hcv
viral
strain
grown
human
hepatoma
cell
line
three
day
infect
cell
permeabil
detect
hcv
foci
carri
use
inactiv
hcvposit
patient
serum
primari
antibodi
peroxidasecoupl
fcspecif
antihuman
iggantibodi
reaction
reveal
dab
peroxidas
substrat
viral
foci
thu
stain
brown
make
easi
count
see
fig
recent
shown
neutral
activ
hcv
antibodi
attenu
serum
factor
associ
hdl
fraction
henc
hdl
abl
facilit
hcvpp
hcvcc
entri
via
mechan
depend
express
scaveng
receptor
bi
srbi
select
lipiduptak
function
view
role
hdl
hcv
entri
immunoglobulin
purifi
serum
sampl
prior
determin
neutral
antibodi
titer
see
fig
specif
hcv
neutral
assay
assess
test
antihcvelisaneg
sampl
includ
five
posit
hepat
b
viru
surfac
antibodi
antihb
five
posit
heterophil
antibodi
sampl
test
neg
two
commerci
antihcv
antibodi
detect
assay
hcv
version
abbott
wiesbaden
germani
antihcv
reagent
pack
orthoclin
diagnost
high
wycomb
unit
kingdom
hcvrnaneg
qualit
commerci
assay
coba
amplicor
hcv
test
version
roch
diagnost
meylan
franc
antihcvneg
sampl
compar
sampl
patient
chronic
infect
hcv
genotyp
neutral
titer
antihcvneg
serum
sampl
shown
fig
mean
valu
correspond
dilut
assay
cutoff
determin
mean
valu
neg
sampl
plu
two
standard
deviat
correspond
dilut
assay
exhibit
specif
sensibl
valu
respect
assay
show
crossreact
antihiv
antihb
heterophil
antibodyposit
sampl
data
shown
convers
chronic
hcv
genotyp
sampl
display
strong
reaction
mean
valu
correspond
dilut
p
interassay
variabl
determin
test
one
hcv
genotyp
sampl
consecut
experi
n
wherea
intraassay
variabl
evalu
test
sampl
time
n
experi
whilst
run
dilut
seri
intraassay
interassay
coeffici
variat
cv
log
neutral
titer
respect
fiftyseven
hcvposit
antibodi
sampl
evalu
use
hcv
focu
reduct
neutral
assay
genotyp
distribut
follow
type
studi
sampl
respect
mean
valu
differ
genotyp
shown
fig
tabl
mean
log
neutral
titer
genotyp
similar
genotyp
genotyp
genotyp
mean
averag
valu
lower
genotyp
genotyp
strikingli
high
heterolog
titer
observ
five
patient
three
infect
hcv
genotyp
two
infect
hcv
genotyp
see
fig
genotyp
sampl
compar
genotyp
correspond
result
nevertheless
indic
neutral
assay
suitabl
genotyp
two
determin
log
neutral
valu
genotyp
respect
result
confirm
presenc
broadli
crossneutr
antibodi
alreadi
report
use
previou
hcv
pseudoparticl
system
hcvpp
distribut
log
neutral
titer
across
hcv
elisa
rnaposit
sampl
function
hcv
genotyp
shown
fig
neutral
antibodi
titer
fell
rang
log
titer
correspond
dilut
respect
overal
sampl
display
titer
greater
log
convers
display
titer
cutoff
valu
ie
log
thu
hcvinfect
patient
two
test
posit
neutral
antibodi
assay
titer
respect
role
neutral
antibodi
acut
chronic
viral
infect
remain
import
question
gener
controversi
result
initi
presenc
neutral
antibodi
shown
control
hcv
load
contribut
viral
erad
patient
capabl
clear
infect
studi
appear
neutral
antibodi
delay
restrict
antibodi
patient
develop
chronic
infect
chimpanze
model
critic
studi
hcv
transmiss
host
immun
respons
howev
neutral
antibodi
detect
anim
resolv
infect
suggest
minim
role
viral
clearanc
also
observ
human
studi
experiment
infect
chimpanze
natur
infect
human
reinfect
homolog
heterolog
hcv
strain
suggest
humor
immun
develop
spontan
resolut
acut
hepat
c
steril
chronic
infect
human
presenc
andor
product
neutral
antibodi
suffic
cure
infect
could
regul
spread
viru
thu
postul
chronic
infect
viral
mutant
continu
escap
renew
product
neutral
antibodi
retrovir
pseudoparticl
use
develop
interest
tool
measur
neutral
antibodi
vitro
assay
demonstr
presenc
hcvneutral
antibodi
human
sera
rel
high
titer
broadli
neutral
activ
differ
hcv
genotyp
howev
model
repres
genuin
hcv
virion
particular
bud
retrovir
particl
thought
differ
may
involv
varieti
cellular
pathway
character
infecti
retrovir
pseudotyp
particl
bear
hcv
glycoprotein
shown
heterogen
possibl
pseudoparticl
may
relev
nativ
hcv
virion
recent
develop
cell
cultur
model
hcv
enabl
product
nativ
hcv
virion
effici
propag
cell
cultur
cell
cultur
system
allow
us
develop
neutral
assay
evalu
level
proport
hcvneutral
antibodi
chronic
infect
hcv
patient
analys
number
paramet
practic
reproduc
specif
test
effect
rang
variabl
viral
inoculum
size
incub
time
fixat
permeabil
method
block
revel
reagent
paramet
data
shown
overal
neutral
assay
describ
studi
perform
similarli
standard
neutral
assay
mani
virus
assay
reli
abil
specif
genotyp
viral
strain
replic
multipli
human
hepatoma
cell
line
cell
cultur
model
enabl
rapid
detect
viral
foci
hour
infect
moreov
secondari
foci
detect
time
point
fixat
paraformaldehyd
permeabil
triton
chosen
order
preserv
antigen
prevent
cell
monolay
detach
wash
develop
dab
peroxid
substrat
made
easi
count
specif
colour
viral
foci
viral
inoculum
size
import
paramet
low
enough
enabl
good
assay
sensit
high
enough
produc
statist
signific
number
foci
ie
allow
reduct
number
foci
thu
effect
neutral
monitor
thu
ffu
use
inoculum
neutral
assay
order
test
differ
human
sampl
take
account
abil
hdl
facilit
hcvcc
entri
via
mechan
depend
express
scaveng
receptor
bi
given
hdl
role
hcv
entri
immunoglobulin
purifi
serum
sampl
prior
determin
neutral
antibodi
titer
free
assay
risk
nonspecif
neutral
activ
serum
via
effect
hdl
complement
system
andor
serum
amyloid
protein
saa
hcv
neutral
assay
exhibit
good
reproduc
duplic
assay
independ
test
expect
intraassay
coeffici
variat
cv
lower
interassay
cv
test
also
show
good
specif
sinc
interact
antihiv
antihbv
heterophil
antibodi
low
titer
found
hcv
elisa
rnaneg
sampl
assay
cutoff
determin
mean
titer
neg
sampl
plu
two
standard
deviat
log
correspond
dilut
given
strain
hcv
genotyp
avail
assay
evalu
neutral
titer
sera
patient
chronic
infect
hcv
genotyp
ie
sera
detect
posit
neutral
assay
except
two
sera
hcv
genotyp
patient
two
sampl
present
high
specif
antibodi
ratio
accord
elisa
low
inhibit
neutral
assay
far
cutoff
fact
conclud
either
sampl
lack
neutral
antibodi
antibodi
present
crossneutr
hcv
genotyp
sensit
genotyp
genotyp
strain
use
assay
also
hcv
genotyp
except
genotyp
hcv
genotyp
antibodi
also
measur
sampl
accur
test
moreov
posit
sera
compar
significantli
high
titer
whatev
genotyp
find
suggest
neutral
antibodi
crossreact
anoth
possibl
patient
previous
infect
genotyp
strain
howev
unlik
genotyp
strain
circul
franc
expect
neutral
test
assay
present
present
studi
appear
specif
independ
genotyp
usabl
circumst
viral
infect
neutral
assay
describ
studi
use
refer
assay
thu
confid
hcvcc
genotyp
becom
avail
assay
replac
pseudoparticl
assay
near
futur
probabl
relev
assay
somewhat
timeconsum
could
simplifi
use
one
dilut
count
foci
howev
type
short
cut
would
make
difficult
extrapol
dilut
neutral
inoculum
anoth
approach
would
consist
use
recombin
hcv
capabl
express
report
gene
luciferas
order
use
singl
dilut
obtain
quantit
result
howev
neutral
studi
use
genotyp
need
order
complet
observ
character
homolog
heterolog
potenc
polyclon
monoclon
neutral
antibodi
simpl
specif
reproduc
cell
culturebas
neutral
assay
develop
determin
neutral
antihcv
antibodi
human
sera
test
import
tool
gaug
relationship
neutral
respons
viral
load
kinet
acut
chronic
infect
patient
human
hepatoma
cell
grown
dulbecco
minimum
essenti
medium
invitrogen
supplement
fetal
bovin
serum
cell
cultur
maintain
plasmid
contain
fulllength
cdna
isol
belong
subtyp
genbank
access
gift
dr
wakita
depart
microbiolog
tokyo
metropolitan
institut
neurosci
tokyo
japan
describ
previous
gener
genom
hcv
rna
plasmid
linear
end
hcv
cdna
use
templat
vitro
transcript
describ
previous
viral
stock
obtain
harvest
cell
cultur
supernat
freez
viru
titrat
perform
cell
microtit
plate
corn
ny
hour
incub
immunostain
cell
antibodi
hcvposit
patient
serum
previous
inactiv
see
section
viru
neutral
assay
viral
titer
determin
triplic
mean
number
foci
express
focu
form
unitsml
ffuml
seventyseven
human
serum
sampl
test
collect
sera
approv
local
ethic
committe
inform
consent
obtain
donor
fiftyseven
sampl
obtain
chronic
infect
hcv
patient
presenc
hcv
antibodi
determin
confirm
use
two
thirdgener
hcv
eia
assay
hcv
version
abbott
wiesbaden
germani
antihcv
reagent
pack
orthoclin
diagnost
high
wycomb
unit
kingdom
hcv
rna
determin
qualit
commerci
assay
coba
amplicor
hcv
test
version
roch
diagnost
meylan
franc
hcv
genotyp
perform
direct
sequenc
describ
elsewher
genotyp
distribut
follow
sampl
type
respect
set
antihcvneg
serum
sampl
use
evalu
assay
specif
includ
five
serum
sampl
posit
hepat
b
viru
surfac
antibodi
antihb
statu
five
sera
epsteinbarr
virusinfect
patient
test
posit
heterophil
antibodi
serum
sampl
store
upon
collect
thaw
time
assay
serum
immunoglobulin
g
igg
fraction
purifi
use
protein
gsepharos
ge
healthcar
orsay
franc
heatinactiv
serum
mix
protein
gsepharos
immunobead
min
centrifug
min
g
supernat
discard
immunobead
wash
time
immunopur
igg
bind
buffer
pierc
rockford
usa
immunopur
igg
elut
buffer
pierc
rockford
usa
ad
immunobead
mix
thoroughli
centrifug
min
g
supernat
pool
neutral
trishcl
ph
igg
concentr
determin
use
bradford
assay
biorad
protein
assay
biorad
marneslacoquett
franc
purifi
igg
store
hcv
focu
reduct
neutral
assay
perform
microtit
plate
serial
dilut
purifi
igg
rang
establish
dilut
test
twice
sampl
mix
viru
ffu
microtit
plate
incub
hour
volum
cell
suspens
cellswel
cultur
medium
ad
incub
hour
hour
supernat
remov
cultur
medium
ad
monolay
hour
cell
fix
paraformaldehyd
permeabil
triton
primari
antibodi
hcvposit
patient
serum
inactiv
dilut
prior
use
incub
h
room
temperatur
peroxidasecoupl
fcspecif
antihuman
igg
antibodi
sigma
saint
quentin
fallavi
franc
dilut
dispens
onto
cell
monolay
incub
min
room
temperatur
reaction
develop
dab
peroxidas
substrat
sigma
saint
quentin
fallavi
franc
stop
min
incub
distil
water
number
hcv
foci
dilut
determin
control
includ
assay
nonneutr
viru
purifi
igg
patient
dilut
dilut
neutral
viru
calcul
curvilinear
regress
analysi
use
xlstat
softwar
addinsoft
sarl
pari
franc
titer
determin
log
valu
reciproc
antibodi
dilut
reduc
number
viral
foci
titer
express
logarithm
valu
mean
standard
deviat
calcul
student
ttest
use
compar
data
group
p
valu
consid
signific
author
declar
compet
interest
cfo
sc
gd
conceiv
design
perform
analysi
cfo
sd
eb
carri
bioassay
sc
cfr
perform
statist
analysi
dc
cw
vt
given
final
approv
version
publish
sc
gd
wrote
paper
author
read
approv
final
manuscript
